Thiago Carvalho on Nostr: 'The new drug, Cobenfy, also influences dopamine levels, but it does so indirectly, ...
'The new drug, Cobenfy, also influences dopamine levels, but it does so indirectly, by changing levels of another neurotransmitter, acetylcholine. The new approach, researchers hope, will address some of the most intractable aspects of the disease, like lack of motivation and inability to feel pleasure'
https://www.nytimes.com/2024/09/26/health/fda-schizophrenia-drug.htmlPublished at
2024-09-27 06:28:24Event JSON
{
"id": "937613f5cb1094e5c6c3626342cfdb6900d213353f6a164c143020e18ba017c6",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1727418504,
"kind": 1,
"tags": [
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/113208099104461470",
"activitypub"
]
],
"content": "'The new drug, Cobenfy, also influences dopamine levels, but it does so indirectly, by changing levels of another neurotransmitter, acetylcholine. The new approach, researchers hope, will address some of the most intractable aspects of the disease, like lack of motivation and inability to feel pleasure'\n\nhttps://www.nytimes.com/2024/09/26/health/fda-schizophrenia-drug.html",
"sig": "50f746b1a5a99bf3681fad98218ef1c3ec33fb8bbbbfb62a7e0f7aef6e8626f2040326a771019319dcb192659b796c006e4e22f7d4e1d54f0fa5596b2054462c"
}
